Beyond fibers and food, the Cannabis sativa plant now powers a fast-growing pharmaceutical and biotech industry. From medicines approved by regulators to molecules designed in the lab, three major hubs lead this scientific race — the United States, Canada and Europe. This is market-context: TGG Wallet tokenizes the agro-industrial backing of hemp (RWA) and does not operate in the pharmaceutical sector, but the plant's scientific maturity reinforces the real value of the whole ecosystem.
Biotech and molecular precision
The U.S. focus splits between isolating natural compounds from the plant and synthesizing molecules in the lab for maximum medical precision.
Jazz / GW Pharmaceuticals: Britain's GW, now part of U.S.-based Jazz, created Epidiolex — the first plant-derived CBD medicine approved by the FDA (2018), for rare and severe childhood epilepsies such as Dravet and Lennox-Gastaut syndromes. It is now sold in more than 35 countries.
Zynerba Pharmaceuticals: a pioneer of transdermal cannabinoid delivery (absorbed through the skin), it developed Zygel, a synthetic-CBD gel studied for Fragile X syndrome. The company became part of Harmony Biosciences in 2023.
IGC Pharma: runs clinical trials (Phases 1 and 2) with cannabinoid-based formulations to treat agitation and symptoms associated with Alzheimer's disease.
Pioneers of global research
One of the first countries to legalize the plant federally, Canada built a robust laboratory ecosystem focused on standardized treatments.
Tilray and Canopy Growth: large Canadian corporations with medical divisions producing pharmaceutical-grade extracts, exported to hospitals in Europe and the Americas for chronic pain relief and palliative care.
Canurta: develops therapies based on rare hemp-derived polyphenols, targeting inflammatory and neurological diseases.
Innocan Pharma: with a presence in Canada and Israel, it researches advanced drug-delivery systems, such as liposome-bound CBD for prolonged relief of chronic pain and epilepsy.
Pharmaceutical rigor and clinical innovation
Europe stands out for tightly controlled medicines and innovative scientific approaches.
GW Pharmaceuticals (United Kingdom): developed Sativex, a THC-and-CBD combination approved in more than 25 countries (outside the U.S.) for muscle spasticity caused by Multiple Sclerosis.
Synendos Therapeutics (Switzerland): rather than extracting from the plant, it designs molecules that modulate the body's own endocannabinoid system, seeking treatments for anxiety and central-nervous-system disorders.
Sanity Group (Germany): one of Central Europe's most prominent cannabinoid companies, it develops medical formulations for neurology and chronic pain, propelled by Germany's broad 2024 law reform.
From childhood epilepsy to multiple sclerosis, cannabinoids are already part of the therapeutic arsenal approved by agencies such as the FDA and the EMA.
What this has to do with TGG Wallet
TGG Wallet does not develop or sell medicines: its infrastructure tokenizes the agro-industrial backing of hemp on the XRPL network. But the plant's scientific consolidation — with approved medicines, billions in investment and research across three continents — is the backdrop that gives the whole chain solidity. The more science validates the uses of Cannabis sativa, the more robust the real-world asset behind the $TGG token becomes.
Agriculture, industry and science converge on the same plant. TGG Wallet connects the real, productive layer of that economy to the world of digital assets.
Liked the article? Share it:
Ready to Be Part of It?
Become an early-stage investor in the TGG Wallet ecosystem and gain access to exclusive vesting conditions and private pools.
Whitepaper WhatsApp